Thus, despite CD33 being expressed on the vast majority of LSCs, the importance of a modular approach with the capacity to simultaneously, or, in the event of antigen escape (or clonal heterogeneity), sequentially target other AML-specific antigens is clear, and is further evidenced by previous work [2, 61]. The gene discussed is CD33; the disease is acute myeloid leukemia.